Findings

What do systematic reviews say?

7 questions · 10 findings · 2 reviews · Oral Health

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 5 · 50%Very low 4 · 40%Low 1 · 10%Moderate 0 · 0%High 0 · 0%

GM-CSF vs sucralfate

Oral mucositis (severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

GM-CSF showed no clear difference in oral mucositis (severe) compared with sucralfate; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 0.54 [0.24, 1.21]
1 study · 40 participants
GRADE not reported

GM-CSF vs sucralfate

Oral mucositis (moderate to severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

GM-CSF showed no clear difference in oral mucositis (moderate to severe) compared with sucralfate; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 0.96 [0.8, 1.14]
1 study · 40 participants
GRADE not reported

Granulocyte-macrophage colony-stimulating factor (GM-CSF), higher dose (1260 to 12,600 micrograms) vs Granulocyte-macrophage colony-stimulating factor (GM-CSF), lower dose (12.6 to 126 micrograms)

Oral mucositis (severe) · breast cancer patients undergoing chemotherapy

Granulocyte-macrophage colony-stimulating factor (GM-CSF), higher… led to higher oral mucositis (severe) compared with granulocyte-macrophage colony-stimulating factor (GM-CSF), lower…; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
RR 2.75 [1.07, 7.04]
1 study · 36 participants
GRADE not reported

GM-CSF vs placebo or no treatment

Oral mucositis (severe) · Adults with cancer receiving treatment

Granulocyte-macrophage colony-stimulating factor (GM-CSF) showed no clear difference in oral mucositis (severe) compared with placebo or no treatment (low certainty).

3 findings from 1 review

Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
BMT/SCT after conditioning for mixed cancers
RR 0.74 [0.33, 1.67]
3 studies · 235 participants
Low
Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
Chemotherapy alone for mixed cancers
RR 0.59 [0.05, 7.11]
2 studies · 65 participants
Very low
Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
RT to head and neck
RR 0.31 [0.01, 7.09]
1 study · 29 participants
Very low

Granulocyte-macrophage colony-stimulating factor (GM-CSF), mouthwash vs Sucralfate mouthwash

Oral mucositis (severe) · Adults receiving radiotherapy to the head and neck

Granulocyte-macrophage colony-stimulating factor (GM-CSF), mouthwash showed no clear difference in oral mucositis (severe) compared with sucralfate mouthwash; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
RT to head and neck
RR 0.54 [0.24, 1.21]
1 study · 40 participants
GRADE not reported

GM-CSF vs placebo or no treatment

Oral mucositis (moderate to severe) · Adults with cancer receiving treatment

It is very uncertain whether granulocyte-macrophage colony-stimulating factor (GM-CSF) changes oral mucositis (moderate to severe) compared with placebo or no treatment (very low certainty).

2 findings from 1 review

Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
RT to head and neck
RR 0.72 [0.49, 1.06]
1 study · 29 participants
Very low
Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
BMT/SCT after conditioning for haematological cancers
RR 0.94 [0.79, 1.13]
1 study · 109 participants
Very low

Granulocyte-macrophage colony-stimulating factor (GM-CSF), mouthwash vs Sucralfate mouthwash

Oral mucositis (moderate to severe) · Adults receiving radiotherapy to the head and neck

Granulocyte-macrophage colony-stimulating factor (GM-CSF), mouthwash showed no clear difference in oral mucositis (moderate to severe) compared with sucralfate mouthwash; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
RT to head and neck
RR 0.96 [0.80, 1.14]
1 study · 40 participants
GRADE not reported